Pharma, Medical Device Provisions Outlined In Korea, EU Free Trade Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Fair, transparent, reasonable and non-discriminatory rules urged for pricing and reimbursement processes.You may also be interested in...
South Korea Drug Pricing Strategies Needed Now, Says Merck KGaA's South Korean President Juergen Koenig
HONG KONG - South Korea needs to clarify drug pricing regulations and speed up its decision-making process for new products if it hopes to attract, or even maintain, investment in the R&D pharmaceutical space
Industry Groups Make Anti-Kickback Pledge To Korean Health Industry
SEOUL - South Korean trade associations representing both multinational and local pharmaceutical companies told the government that their members will accept the government's new guidelines that classify meals provided to doctors and pharmacists worth more than KRW 100,000 ($80) as illegal kickbacks
Korea-EU Free Trade Agreement Creates Another Threat To Local Korean Pharmas; Good For MNCs
SEOUL - The conclusion of the Free Trade Agreement talks on July 13 with the European Union could deal another blow to generic-dependent local South Korean pharma companies, already hit by a similar pact pending with the U.S
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: